Clinical Trials Logo

Adenocarcinoma in Situ clinical trials

View clinical trials related to Adenocarcinoma in Situ.

Filter by:

NCT ID: NCT06031181 Recruiting - Lung Adenocarcinoma Clinical Trials

Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)

Start date: March 31, 2023
Phase: Phase 3
Study type: Interventional

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1019. The goal of this clinical trial is to confirm the therapeutic effect of sublobar resection for AIS/MIA diagnosed by intraoperative frozen section.

NCT ID: NCT05613283 Active, not recruiting - Cervical Cancer Clinical Trials

Primary Cervical Cancer Screening by Self-sampling HPV Test

PREVENT
Start date: November 19, 2022
Phase:
Study type: Observational

Cervical cancer seriously threatens women's health and HPV infection is the main cause of cervical cancer. Traditionally, Cervical cancer screening is based on cervical exfoliated cell samples collected by health care provider, which is labor consuming and the coverage and compliance are both relatively low in some areas. Non-invasive hrHPV self-sampling test appears to be more acceptable and may improve the HPV screening coverage. This study aims to evaluate the clinical performance of a newly developed urine/vaginal self-sampling hrHPV test in Cervical cancer screening.

NCT ID: NCT05210348 Recruiting - Cervical Cancer Clinical Trials

Clinical Evaluation of Detection of High Risk HPV in Urine

Urine-hrHPV
Start date: September 15, 2021
Phase:
Study type: Observational

Cervical cancer is one of the most common tumors in women, which seriously threatens women's life quality and safety. Human papilloma virus (HPV) infection is the most common cause of cervical cancer. Traditional HPV testing is based on the cells sample shed from the cervix. Recent studies have shown that urine HPV detection can be used as a new HPV detection method. This study intends to include patients undergoing TCT /HPV test/colposcopy in the department of gynecological diseases of the hospital, and collect urine samples and cervical swab samples. Sanger sequencing and cervical swab HPV test results were compared to evaluate the accuracy and clinical validity of urine HPV test combined with clinical diagnosis results of cases.

NCT ID: NCT04755517 Enrolling by invitation - Clinical trials for Cervical Intraepithelial Neoplasia Grade 2/3

Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)

HPV400
Start date: June 9, 2020
Phase: N/A
Study type: Interventional

To identify: 1) Whether being informed infrequently results about screening is at least as a) safe and b) accurate as frequently obtaining all information from (the present combination of opportunistic/organized) cervical screening by comparing regimen results of two screening visits at the ages of 25 and 28 years (Arm A1) vs. results of one screening visit at the age of 28 years (Arm A2) in unvaccinated herd effect protected women. Unvaccinated, frequently screened women, who are not under herd effect protection will be controls (C).

NCT ID: NCT04452058 Recruiting - Lung Cancer Clinical Trials

CT-based Radiomic Algorithm for Assisting Surgery Decision and Predicting Immunotherapy Response of NSCLC

TOP-RLC
Start date: August 1, 2019
Phase:
Study type: Observational

The purpose of this study was to investigate whether the combined radiomic model based on radiomic features extracted from focus and perifocal area (5mm) can effectively improve prediction performance of distinguishing precancerous lesions from early-stage lung adenocarcinoma, which could assist clinical decision making for surgery indication. Besides, response and long term clinical benefit of immunotherapy of advanced NSCLC lung cancer patients could also be predicted by this strategy.

NCT ID: NCT03546842 Completed - Clinical trials for Uterine Cervical Neoplasms

Safety and Immunogenicity Study of V503 (GARDASILâ„¢9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

Start date: June 29, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and immunogenicity of V503 (GARDASILâ„¢9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam. The study hypothesis states that V503 induces acceptable anti-human papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion at 4 weeks postdose 3.

NCT ID: NCT03493542 Completed - Clinical trials for Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

Start date: August 31, 2018
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the immunogenicity, safety, and tolerability of Gardasil® (quadrivalent human papillomavirus [qHPV] vaccine, V501) in Chinese girls aged 9-19 years and young women aged 20-26 years. The primary hypothesis of the study states that at 1 month postdose 3, a 3-dose regimen of V501 induces non-inferior geometric mean titers (GMTs) for serum anti-HPV 6, anti-HPV 11, anti-HPV 16, anti-HPV 18 in girls aged 9-19 years compared to young women aged 20-26 years.

NCT ID: NCT03053544 Completed - Clinical trials for Rectal Neoplasm Carcinoma in Situ Adenocarcinoma

Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer

Start date: December 8, 2016
Phase: Phase 2
Study type: Interventional

This study is a phase II, single arm, controlled, open label internal pilot.

NCT ID: NCT02937155 Active, not recruiting - Clinical trials for Adenocarcinoma in Situ

In the Era of the HPV Vaccine, What Are The Current HPV Subtypes Contributing to High Grade Cervical Dysplasia, Adenocarcinoma in Situ, and Early Cervical Cancer?

Start date: November 2016
Phase:
Study type: Observational

This study will look at cervical tissue samples in women with abnormal cervical cells to see if the frequency of the HPV 16/18 subtypes has changed in female populations today, after the introduction of the HPV vaccine. It will compare women who have been exposed to the HPV vaccine with those who have not.

NCT ID: NCT02206048 Completed - Cervix Carcinoma Clinical Trials

Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix

Start date: October 2, 2015
Phase: N/A
Study type: Interventional

The goal of this clinical research study is to learn if it is possible to get high-resolution microendoscopy (HRME) images of AIS tissue and/or tissue from microinvasive carcinoma right before a biopsy of the cervix. Researchers also want to learn if HRME images can show the difference between cancerous tissue and normal cervical tissue.